Sign inJoin free

Watch / Small Cap

Rhythm's cancer test hits high note

19 Nov 20243:37

Rhythm's cancer test hits high note

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

David Atkins, CEO of Rhythm Biosciences (ASX: RHY) shares that the company plans to raise $3.5M through a private placement to advance their cancer detection technologies. The funds will support the development and validation of their colorectal cancer assay alongside five additional cancer programs.

David highlights that while colorectal cancer remains the primary focus, Rhythm (ASX: RHY) is exploring biomarkers for lung, gastric, breast, and pancreatic cancers aiming for a low-cost, non-invasive blood test. They are collaborating with a US partner, with plans for laboratory and clinical testing in Melbourne.

Commercialisation is anticipated for 2025. David emphasises that Rhythm (ASX: RHY), with its advanced biotech program, offers a compelling investment opportunity. The knowledge and progress made in cancer research set a promising stage for the company’s growth and investor engagement.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy